Therapeutic Drug Monitoring and Individualized Medicine of Dasatinib: Focus on Clinical Pharmacokinetics and Pharmacodynamics

Overview

Journal Front Pharmacol

Date 2021 Dec 23

PMID 34938198

Citations 13

Authors

Shiyu He

Jialu Bian

Qianhang Shao

Ying Zhang

Xu Hao

Xingxian Luo

Yufei Feng

Lin Huang

Affiliations

Soon will be listed here.

Abstract

Dasatinib is an oral second-generation tyrosine kinase inhibitor known to be used widely in Philadelphia chromosome-positive (Ph) chronic myeloid leukemia (CML) and Ph acute lymphoblastic leukemia (ALL). Notably, although a high pharmacokinetic variability in patients and an increased risk of pleural effusion are attendant, fixed dosing remains standard practice. Retrospective studies have suggested that dasatinib exposure may be associated with treatment response (efficacy/safety). Therapeutic drug monitoring (TDM) is gradually becoming a practical tool to achieve the goal of individualized medicine for patients receiving targeted drugs. With the help of TDM, these patients who maintain response while have minimum adverse events may achieve long-term survival. This review summaries current knowledge of the clinical pharmacokinetics variation, exposure-response relationships and analytical method for individualized dosing of dasatinib, in particular with respect to therapeutic drug monitoring. In addition, it highlights the emerging insights into several controversial issues in TDM of dasatinib, with the aim of presenting up-to-date evidence for clinical decision-making and insights for future studies.

Citing Articles

Biopharmaceutical and pharmacokinetic attributes to drive nanoformulations of small molecule tyrosine kinase inhibitors.

Mukherjee S, Joshi V, Reddy K, Singh N, Das P, Datta P Asian J Pharm Sci. 2024; 19(6):100980.

PMID: 39640056 PMC: 11617995. DOI: 10.1016/j.ajps.2024.100980.

Solid Self Nano-Emulsifying Drug Delivery System of Dasatinib: Optimization, , and assessment.

Ateeq M, Mahajan S, Saren B, Aalhate M, Singh H, Chatterjee E Ther Deliv. 2024; 15(10):749-768.

PMID: 39287183 PMC: 11457667. DOI: 10.1080/20415990.2024.2397330.

Varying concentrations of tyrosine kinase inhibitors in chronic myeloid leukemia patients following bariatric surgery: a case series.

Lau C, van Kesteren C, Cao Y, Smeenk R, Daenen L, Janssen J Ann Hematol. 2024; 103(11):4765-4771.

PMID: 39129028 PMC: 11534994. DOI: 10.1007/s00277-024-05924-4.

Exploring the causal relationship between glutamine metabolism and leukemia risk: a Mendelian randomization and LC-MS/MS analysis.

Li N, Wang T, Zhang H, Li X, Bai H, Lu N Front Immunol. 2024; 15:1418738.

PMID: 39050845 PMC: 11265999. DOI: 10.3389/fimmu.2024.1418738.

Polymeric Amorphous Solid Dispersions of Dasatinib: Formulation and Ecotoxicological Assessment.

Sokac K, Miloloza M, Kucic Grgic D, Zizek K Pharmaceutics. 2024; 16(4).

PMID: 38675212 PMC: 11053848. DOI: 10.3390/pharmaceutics16040551.

References

Takahashi N, Miura M, Scott S, Niioka T, Sawada K . Pharmacokinetics of dasatinib for Philadelphia-positive acute lymphocytic leukemia with acquired T315I mutation. J Hematol Oncol. 2012; 5:23. PMC: 3409074. DOI: 10.1186/1756-8722-5-23. View

Cortes J, Rousselot P, Kim D, Ritchie E, Hamerschlak N, Coutre S . Dasatinib induces complete hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in blast crisis. Blood. 2006; 109(8):3207-13. DOI: 10.1182/blood-2006-09-046888. View

Kamath A, Wang J, Lee F, Marathe P . Preclinical pharmacokinetics and in vitro metabolism of dasatinib (BMS-354825): a potent oral multi-targeted kinase inhibitor against SRC and BCR-ABL. Cancer Chemother Pharmacol. 2007; 61(3):365-76. DOI: 10.1007/s00280-007-0478-8. View

Yu H, Steeghs N, Nijenhuis C, Schellens J, Beijnen J, Huitema A . Practical guidelines for therapeutic drug monitoring of anticancer tyrosine kinase inhibitors: focus on the pharmacokinetic targets. Clin Pharmacokinet. 2014; 53(4):305-25. DOI: 10.1007/s40262-014-0137-2. View

Koller D, Vaitsekhovich V, Mba C, Steegmann J, Zubiaur P, Abad-Santos F . Effective quantification of 11 tyrosine kinase inhibitors and caffeine in human plasma by validated LC-MS/MS method with potent phospholipids clean-up procedure. Application to therapeutic drug monitoring. Talanta. 2019; 208:120450. DOI: 10.1016/j.talanta.2019.120450. View

Ezzeldin E, Iqbal M, Herqash R, ElNahhas T . Simultaneous quantitative determination of seven novel tyrosine kinase inhibitors in plasma by a validated UPLC-MS/MS method and its application to human microsomal metabolic stability study. J Chromatogr B Analyt Technol Biomed Life Sci. 2019; 1136:121851. DOI: 10.1016/j.jchromb.2019.121851. View

Luo F, Barrett Y, Yang Z, Camuso A, McGlinchey K, Wen M . Identification and validation of phospho-SRC, a novel and potential pharmacodynamic biomarker for dasatinib (SPRYCEL), a multi-targeted kinase inhibitor. Cancer Chemother Pharmacol. 2008; 62(6):1065-74. DOI: 10.1007/s00280-008-0699-5. View

Porkka K, Koskenvesa P, Lundan T, Rimpilainen J, Mustjoki S, Smykla R . Dasatinib crosses the blood-brain barrier and is an efficient therapy for central nervous system Philadelphia chromosome-positive leukemia. Blood. 2008; 112(4):1005-12. DOI: 10.1182/blood-2008-02-140665. View

Mizuta S, Sawa M, Tsurumi H, Matsumoto K, Miyao K, Hara T . Plasma concentrations of dasatinib have a clinical impact on the frequency of dasatinib dose reduction and interruption in chronic myeloid leukemia: an analysis of the DARIA 01 study. Int J Clin Oncol. 2018; 23(5):980-988. PMC: 6154123. DOI: 10.1007/s10147-018-1300-9. View

10.

Yago M, Frymoyer A, Benet L, Smelick G, Frassetto L, Ding X . The use of betaine HCl to enhance dasatinib absorption in healthy volunteers with rabeprazole-induced hypochlorhydria. AAPS J. 2014; 16(6):1358-65. PMC: 4389759. DOI: 10.1208/s12248-014-9673-9. View

11.

Copland M, Hamilton A, Elrick L, Baird J, Allan E, Jordanides N . Dasatinib (BMS-354825) targets an earlier progenitor population than imatinib in primary CML but does not eliminate the quiescent fraction. Blood. 2006; 107(11):4532-9. DOI: 10.1182/blood-2005-07-2947. View

12.

Shah N, Kasap C, Weier C, Balbas M, Nicoll J, Bleickardt E . Transient potent BCR-ABL inhibition is sufficient to commit chronic myeloid leukemia cells irreversibly to apoptosis. Cancer Cell. 2008; 14(6):485-93. DOI: 10.1016/j.ccr.2008.11.001. View

13.

Climent N, Plana M . Immunomodulatory Activity of Tyrosine Kinase Inhibitors to Elicit Cytotoxicity Against Cancer and Viral Infection. Front Pharmacol. 2019; 10:1232. PMC: 6813222. DOI: 10.3389/fphar.2019.01232. View

14.

Iwamoto T, Monma F, Ohishi K, Umino A, Suzuki K, Oka K . Evaluation of Medication Adherence and Pharmacokinetics of Dasatinib for Earlier Molecular Response in Japanese Patients With Newly Diagnosed Chronic Myeloid Leukemia: A Pilot Study. Ther Drug Monit. 2019; 41(5):575-581. DOI: 10.1097/FTD.0000000000000639. View

15.

Weersma R, Zhernakova A, Fu J . Interaction between drugs and the gut microbiome. Gut. 2020; 69(8):1510-1519. PMC: 7398478. DOI: 10.1136/gutjnl-2019-320204. View

16.

Dessilly G, Elens L, Panin N, Karmani L, Demoulin J, Haufroid V . ABCB1 1199G>A polymorphism (rs2229109) affects the transport of imatinib, nilotinib and dasatinib. Pharmacogenomics. 2016; 17(8):883-90. DOI: 10.2217/pgs-2016-0012. View

17.

Uchiyama T, Sato N, Narita M, Yamahira A, Iwabuchi M, Furukawa T . Direct effect of dasatinib on proliferation and cytotoxicity of natural killer cells in in vitro study. Hematol Oncol. 2012; 31(3):156-63. DOI: 10.1002/hon.2034. View

18.

Shah N, Rousselot P, Schiffer C, Rea D, Cortes J, Milone J . Dasatinib in imatinib-resistant or -intolerant chronic-phase, chronic myeloid leukemia patients: 7-year follow-up of study CA180-034. Am J Hematol. 2016; 91(9):869-74. PMC: 5094534. DOI: 10.1002/ajh.24423. View

19.

Maher H, Alzoman N, Shehata S, Abanmy N . Validated UPLC-MS/MS method for the quantification of dasatinib in plasma: Application to pharmacokinetic interaction studies with nutraceuticals in Wistar rats. PLoS One. 2018; 13(6):e0199208. PMC: 6002064. DOI: 10.1371/journal.pone.0199208. View

20.

Huynh H, Pressiat C, Sauvageon H, Madelaine I, Maslanka P, Lebbe C . Development and Validation of a Simultaneous Quantification Method of 14 Tyrosine Kinase Inhibitors in Human Plasma Using LC-MS/MS. Ther Drug Monit. 2016; 39(1):43-54. DOI: 10.1097/FTD.0000000000000357. View